FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease (Q50954570)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 July 2015

Language	Label	Description	Also known as
English	FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease	scientific article published on 15 July 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

chronic obstructive pulmonary disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Donald A Mahler

1

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

Edward Kerwin

2

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

Tim Ayers

3

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

Angel FowlerTaylor

4

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

Samopriyo Maitra

5

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

Chau Thach

6

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

Mark Lloyd

7

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

Francesco Patalano

8

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

Donald Banerji

9

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

language of work or name

0 references

publication date

15 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

American Journal of Respiratory and Critical Care Medicine

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

192

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

9

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

1068-1079

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

Frequent utilization of the emergency department for acute exacerbation of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

A graphical approach to sequentially rejective multiple test procedures

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Minimal clinically important differences in pharmacological trials

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Minimal clinically important differences in COPD lung function

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Interpreting thresholds for a clinically significant change in health status in asthma and COPD.

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

The MCID of the transition dyspnea index is a total score of one unit

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter?

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Patterns of comorbidities in newly diagnosed COPD and asthma in primary care

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Cognitive performance in patients with COPD.

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD.

1 reference

https://api.crossref.org/works/10.1164/RCCM.201505-1048OC

21 January 2018

Identifiers

10.1164/RCCM.201505-1048OC

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26177074

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50954570&oldid=2263986917"